WO2001027154A3 - Membrane translocating peptide drug delivery system - Google Patents

Membrane translocating peptide drug delivery system Download PDF

Info

Publication number
WO2001027154A3
WO2001027154A3 PCT/IB2000/001491 IB0001491W WO0127154A3 WO 2001027154 A3 WO2001027154 A3 WO 2001027154A3 IB 0001491 W IB0001491 W IB 0001491W WO 0127154 A3 WO0127154 A3 WO 0127154A3
Authority
WO
WIPO (PCT)
Prior art keywords
mtlp
active agent
complex
active
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001491
Other languages
French (fr)
Other versions
WO2001027154A2 (en
Inventor
Daniel J O'mahony
Imelda J Lambkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2386231A priority Critical patent/CA2386231C/en
Priority to DE60027030T priority patent/DE60027030D1/en
Priority to AU78110/00A priority patent/AU7811000A/en
Priority to JP2001530372A priority patent/JP4799790B2/en
Priority to EP00968159A priority patent/EP1230267B1/en
Publication of WO2001027154A2 publication Critical patent/WO2001027154A2/en
Anticipated expiration legal-status Critical
Publication of WO2001027154A3 publication Critical patent/WO2001027154A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to an MTLP-active agent complex and an MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.
PCT/IB2000/001491 1999-09-27 2000-09-27 Membrane translocating peptide drug delivery system Ceased WO2001027154A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2386231A CA2386231C (en) 1999-09-27 2000-09-27 Membrane translocating peptide drug delivery system
DE60027030T DE60027030D1 (en) 1999-09-27 2000-09-27 MEMBRANE TRANSLLATING PEPTIDE AS AN ACTIVE TRANSPORT SYSTEM
AU78110/00A AU7811000A (en) 1999-09-27 2000-09-27 Membrane translocating peptide drug delivery system
JP2001530372A JP4799790B2 (en) 1999-09-27 2000-09-27 Membrane translocation peptide, composition containing the peptide, pharmaceutical preparation containing the peptide, and use in preparation of the preparation of the peptide
EP00968159A EP1230267B1 (en) 1999-09-27 2000-09-27 Membrane translocating peptide drug delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15624699P 1999-09-27 1999-09-27
US60/156,246 1999-09-27

Publications (2)

Publication Number Publication Date
WO2001027154A2 WO2001027154A2 (en) 2001-04-19
WO2001027154A3 true WO2001027154A3 (en) 2002-06-20

Family

ID=22558739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001491 Ceased WO2001027154A2 (en) 1999-09-27 2000-09-27 Membrane translocating peptide drug delivery system

Country Status (7)

Country Link
EP (1) EP1230267B1 (en)
JP (1) JP4799790B2 (en)
AT (1) ATE321782T1 (en)
AU (1) AU7811000A (en)
CA (1) CA2386231C (en)
DE (1) DE60027030D1 (en)
WO (1) WO2001027154A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335509B2 (en) 1995-01-23 2008-02-26 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US10323072B2 (en) 2015-08-18 2019-06-18 Cellivery Therapeutics, Inc. Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof
US10385103B2 (en) 2014-08-27 2019-08-20 Cellivery Therapeutics, Inc. Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
US10508265B2 (en) 2015-08-10 2019-12-17 Cellivery Therapeutics, Inc. Cell-permeable reprogramming factor (iCP-RF) recombinant protein and use thereof
US10669531B2 (en) 2015-08-10 2020-06-02 Cellivery Therapeutics, Inc. Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181367A1 (en) * 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
DE60229867D1 (en) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd TARGETED LIGANDS AGAINST PEYER'S FLAKE AND / OR M CELLS
JP2005511761A (en) * 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ Nanoparticle delivery vehicle
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
CN107074910B (en) * 2014-08-17 2022-02-18 塞里维瑞疗法公司 Higher macromolecule transduction domain sequences, polynucleotides encoding same, and uses thereof
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
WO1999049879A1 (en) * 1998-03-31 1999-10-07 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO1999064449A2 (en) * 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3618111B2 (en) * 1993-11-05 2005-02-09 株式会社 メドレックス Method for delivering useful substance and membrane recognition signal
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
WO1999049879A1 (en) * 1998-03-31 1999-10-07 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO1999064449A2 (en) * 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EASON PD & IMPERIALI B: "A Potent Oligosaccharyl Transferase Inhibitor That Crosses the Intracellular Endoplasmic Reticulum Membrane", BIOCHEMISTRY, vol. 38, 4 August 1999 (1999-08-04), pages 5430 - 5437, XP002182597 *
LIN YZ ET AL.: "Inhibition of Nuclear Translocation of Transcription Factor NK-kappaB by a synthetic peptide containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 24, 16 June 1995 (1995-06-16), pages 14255 - 14258, XP002050723 *
NEZIL FA & BLOOM M: "Combined influence of cholesterol and synthetic amphiphillic peptides upon bilayer thickness in model membranes", BIOPHYSICAL JOURNAL, vol. 61, May 1992 (1992-05-01), pages 1176 - 1183, XP001031328 *
ROJAS M ET AL.: "Genetic engineering of proteins with cell membrane permeability", NATURE BIOTECHNOLOGY, vol. 16, April 1998 (1998-04-01), pages 370 - 375, XP002182596 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335509B2 (en) 1995-01-23 2008-02-26 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US7361640B2 (en) 1995-01-23 2008-04-22 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US10787492B2 (en) 2014-08-27 2020-09-29 Cellivery Therapeutics, Inc. Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof
US10385103B2 (en) 2014-08-27 2019-08-20 Cellivery Therapeutics, Inc. Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
US10774123B2 (en) 2014-08-27 2020-09-15 Cellivery Therapeutics, Inc. Cell-permeable bone morphogenetic protein (CP-BMP) recombinant protein and use thereof
US10781241B2 (en) 2014-08-27 2020-09-22 Cellivery Therapeutics, Inc. Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof
US10961292B2 (en) 2014-08-27 2021-03-30 Cellivery Therapeutics, Inc. Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
US10975132B2 (en) 2014-08-27 2021-04-13 Cellivery Therapeutics, Inc. Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
US11279743B2 (en) 2014-08-27 2022-03-22 Cellivery Therapeutics, Inc. Cell-permeable bone morphogenetic protein (CPBMP) recombinant protein and use thereof
US10508265B2 (en) 2015-08-10 2019-12-17 Cellivery Therapeutics, Inc. Cell-permeable reprogramming factor (iCP-RF) recombinant protein and use thereof
US10669531B2 (en) 2015-08-10 2020-06-02 Cellivery Therapeutics, Inc. Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof
US10689424B2 (en) 2015-08-18 2020-06-23 Cellivery Therapeutics, Inc. Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof
US10323072B2 (en) 2015-08-18 2019-06-18 Cellivery Therapeutics, Inc. Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof

Also Published As

Publication number Publication date
CA2386231A1 (en) 2001-04-19
DE60027030D1 (en) 2006-05-18
AU7811000A (en) 2001-04-23
EP1230267B1 (en) 2006-03-29
ATE321782T1 (en) 2006-04-15
EP1230267A2 (en) 2002-08-14
JP2003511464A (en) 2003-03-25
WO2001027154A2 (en) 2001-04-19
JP4799790B2 (en) 2011-10-26
CA2386231C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
WO2001027154A3 (en) Membrane translocating peptide drug delivery system
Eklund et al. Structural comparisons of mammalian, yeast and bacillar alcohol dehydrogenases
Egleton et al. Transport of opioid peptides into the central nervous system
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
EP2570429A3 (en) Peptide vaccines with Seq ID No: 48, 41, 44, 46 or 78 for cancers expressing tumor-associated antigens
WO1999007839A3 (en) Immunoprotective influenza antigen and its use in vaccination
PT1091975E (en) NEW CYCLOSPORINE WITH AN IMPROVED ACTIVITY PROFILE
WO2001080896A3 (en) Flavopiridol drug combinations and methods with reduced side effects
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
WO2000025725A3 (en) Functional antagonists of hedgehog activity
WO2009025116A1 (en) Cdh3 peptide and medicinal agent comprising the same
GB0100551D0 (en) Protein
AU7134898A (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
WO2002016617A3 (en) Myrosinase from brevicoryne brassicae
WO2001005811A3 (en) Cyclic peptidomimetic urokinase receptor antagonists
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
WO2003006492A3 (en) Biologically active peptides
GB2411404A (en) Biologically active peptide conjugates
WO1998053838A3 (en) A soluble laminin receptor precursor and methods to inhibit its interactions
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
AUPO089396A0 (en) Neuroactive peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DZ EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 530372

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2386231

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000968159

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CU CZ DE DK DZ EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000968159

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000968159

Country of ref document: EP